Studies have shown that collaborative parent-child relationships can positively influence both regimen adherence and glycemic control, 1 and that regimen adherence is improved by parental involvement 2 and monitoring of their child's diabetes-related tasks. 3 We hypothesized that immediate access to diabetes-related data and the ability to review these data retrospectively may increase feelings of confidence/safety in diabetes management and reduce hypoglycemia fear among parents of children/adolescents with type 1 diabetes (T1D).
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The Accu-Chek® Connect System (Roche Diabetes Care, Indianapolis, USA) consists of a blood glucose meter, smartphone application (app) and an online data management web portal. The meter connects wirelessly, via low-energy Bluetooth, to the user's smartphone app, which provides multiple functions to facilitate diabetes management. The system allows users to share real-time glucose data and related information with others through a personal web portal and/or text message.
In this 1-week, observational, mono-centric pilot study, we assessed perceptions of parents of children/adolescents (age 0-17 years) with type 1 diabetes and older children/adolescents (age 8-17 years) who used the system while attending the Friends for Life Conference, held July 6-12, 2015, at Disney's Coronado Springs Resort, Florida. Participants received the system blood glucose meter, testing supplies, and a smartphone (if needed) and underwent a 15-minute training session on system use. Participants were asked to use the system for 3 or more days.
Pre and post questionnaires were used to assess system use and impact on perceptions of confidence, safety, hypoglycemia fear, system utility and preference to current diabetes management method. A total of 91 parents of T1D children/adolescents and 79 T1D children/adolescents are included in this analysis.
A large majority of parents and children/adolescents reported frequent use of the meter (83.5% and 96.2%, respectively) and smartphone app (65.9% and 87.3%, respectively). The majority of respondents "mostly agreed" that they felt more confident, safer and less worry about hypoglycemia when using the system (Figure 1 ). Comparison of continuous glucose monitoring (CGM) versus no CGM use showed notable differences in the percentage of parents who reported feelings of increased safety (68.4% vs 80.0%, P = .4437, respectively) and less fear of hypoglycemia (61.4% vs 83.3%, respectively, P = .0521).
Most parent (73.6%) and children/adolescent (64.6%) respondents reported a preference for using the system over their prior diabetes management method. A notable difference was seen in preference for using the system over previous method between parents of multiple daily insulin injections (MDI)-versus continuous subcutaneous insulin infusion (CSII)-treated children (84.0% vs 69.7%, respectively, P = .1941). Similar perceptions were reported by children/adolescent CGM versus no CGM users: increased safety (62.5% vs 82.1%, P = .0632, respectively) and less fear of hypoglycemia (60.4% vs 78.6%, respectively, P = .0745). Most parents (90.1%) and children/adolescents (93.7%) reported satisfaction with how the system helped them manage diabetes. Most respondents (86.8% parents, 86.1% children/adolescents) reported overall satisfaction with system.
Our study demonstrates that ease of use, combined with accurate, real-time access to glucose data in a device that is easy to learn and adopt can facilitate daily diabetes care, reduce patient and parent anxiety and fear, and support adherence to good self-management practices.
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